演題詳細

ポスター / Poster

ポスター 32 (Poster 32) :悪性リンパ腫:治療

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
磯部 泰司 (Yasushi Isobe):1
1:聖マリアンナ医科大学 血液・腫瘍内科
 
前へ戻る

Concurrent chemoradiotherapy in combination with IMRT for localized nasal NK/T-cell lymphoma

演題番号 : PS-1-237

丸山 聡 (Satoshi Maruyama):1、辻村 秀樹 (Hideki Tsujimura):1、山田 修平 (Shuhei Yamada):1、菅原 武明 (Takeaki Sugawara):1、伊勢 美樹子 (Mikiko Ise):1、酒井 力 (Chikara Sakai):1、味八木 寿子 (Toshiko Miyaki):1、王 暁斐 (Xiaofei Wang):1、熊谷 匡也 (Kyoya Kumagai):1

1:Division of Hematology-Oncology, Chiba Cancer Center, Japan

 

[Background] Extranodal NK/T-cell lymphoma (ENKL), nasal type shows poor response to conventional chemotherapy. Therefore radiotherapy has been established as a useful modality for localized disease. Recent progress has shown superior outcome with the combination of concurrent radiotherapy and chemotherapy. Currently, 50Gy of radiation with two thirds DeVIC regimen, demonstrated by JCOG0211 trial, is considered as one of the standard therapy for limited-staged disease. Intensity modulated radiotherapy (IMRT) is an advanced technology that supplies precious tumor targeting with reduced complications than conventional way. Here we employ new approach by using high dose IMRT with DeVIC in the treatment of ENKL. [Methods] Patients with newly diagnosed localized nasal ENKL underwent 60Gy of concurrent IMRT with 3 cycles of two thirds DeVIC. Eight patients with stage IE disease were assessed. [Results] All patients completed scheduled treatment without remarkable delay. Although G4 neutropenia was common, no documented infections were observed. Radiation-related mucositis seen in all cases (G2/3=3/5 patients) was transient and manageable. All of 8 patients achieved complete response. Two patients developed systemic recurrence soon after the treatment and died of disease. Importantly, their nasal sites were controlled. With median follow up of 26(4-46) months, 6 patients remain alive without recurrence and late onset toxicities. [Conclusions] Combination of IMRT and DeVIC potentially provides high efficacy in local control of nasal ENKL with tolerable adverse effects.

前へ戻る